What is the total potential value of Eli Lilly's acquisition of AtaiBeckley, including both upfront payment and milestone payments?

The total potential value of Eli Lilly's acquisition of AtaiBeckley is up to $3.8 billion: $2.8 billion in upfront payment for all outstanding shares at $6.75 per share, plus up to $1 billion in potential milestone payments at $2.50 per share.

Why is Eli Lilly acquiring AtaiBeckley, according to the news?

Eli Lilly is acquiring AtaiBeckley to expand its neuroscience profile and gain a foothold in the growing psychedelics arena.

Eli Lilly to Acquire Psychedelic-Drug Firm AtaiBeckley

Jul 16, 2026

Eli Lilly agreed to acquire biotech firm AtaiBeckley for $2.8 billion upfront plus potential milestones, expanding its neuroscience portfolio into the psychedelics market.

cen

2026-02-03

Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms

2026-03-31

Eli Lilly to Acquire Narcolepsy Drug Developer for $6.3 Billion

2026-04-29

Eli Lilly Investors Eager for Foundayo Insight After Early Launch Data

2026-04-30

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

2026-04-30

US Premarket Movers for April 30, 2026